Notch-independent RBPJ controls angiogenesis in the adult heart

Ramón Díaz-Trelles (), Maria Cecilia Scimia, Paul Bushway, Danh Tran, Anna Monosov, Edward Monosov, Kirk Peterson, Stacey Rentschler, Pedro Cabrales, Pilar Ruiz-Lozano and Mark Mercola ()
Additional contact information
Ramón Díaz-Trelles: Sanford Burnham Prebys Medical Discovery Institute
Maria Cecilia Scimia: Sanford Burnham Prebys Medical Discovery Institute
Paul Bushway: Sanford Burnham Prebys Medical Discovery Institute
Danh Tran: Sanford Burnham Prebys Medical Discovery Institute
Anna Monosov: Sanford Burnham Prebys Medical Discovery Institute
Edward Monosov: Sanford Burnham Prebys Medical Discovery Institute
Kirk Peterson: University of California, San Diego
Stacey Rentschler: Developmental Biology and Biomedical Engineering, Washington University
Pedro Cabrales: Jacobs School of Engineering, University of California
Pilar Ruiz-Lozano: Stanford University
Mark Mercola: Sanford Burnham Prebys Medical Discovery Institute

Nature Communications, 2016, vol. 7, issue 1, 1-10

Abstract: Abstract Increasing angiogenesis has long been considered a therapeutic target for improving heart function after injury such as acute myocardial infarction. However, gene, protein and cell therapies to increase microvascularization have not been successful, most likely because the studies failed to achieve regulated and concerted expression of pro-angiogenic and angiostatic factors needed to produce functional microvasculature. Here, we report that the transcription factor RBPJ is a homoeostatic repressor of multiple pro-angiogenic and angiostatic factor genes in cardiomyocytes. RBPJ controls angiogenic factor gene expression independently of Notch by antagonizing the activity of hypoxia-inducible factors (HIFs). In contrast to previous strategies, the cardiomyocyte-specific deletion of Rbpj increased microvascularization of the heart without adversely affecting cardiac structure or function even into old age. Furthermore, the loss of RBPJ in cardiomyocytes increased hypoxia tolerance, improved heart function and decreased pathological remodelling after myocardial infarction, suggesting that inhibiting RBPJ might be therapeutic for ischaemic injury.

Date: 2016
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms12088 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms12088

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms12088

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().